生科院专题学术讲座 | Xue HAN: Manipulating Immunomodulation Pathway to Treat Both Cancer and Autoimmune Disease

来源:生命科学学院 发布时间:2019-12-23 作者:生命科学学院

时间:2019年12月25日(周三)10:00-11:30

Time10:00-11:30, Wednesday, December 25, 2019

地点:西湖大学云栖校区5号楼1楼学术报告厅

Venue: Lecture Hall, 1st Floor, Build 5, Yunqi Campus

主持人:西湖大学生命科学学院 许田教授

HostProf. Tian XU, School of Life Sciences, Westlake University


主讲嘉宾/Speaker:


Dr. Xue HAN


主讲人简介/Biography:

Dr. Xue Han obtained her Ph.D. from Institute of Biophysics, Chinese Academy of Sciences in 2011. Same year, she joined Dr. Lieping Chen’s lab at Yale University as a postdoc associate and became an associate research scientist five years later. Dr. Han has worked to characterize new therapeutic targets for immunotherapy to treat cancer, inflammation, and autoimmune disease. Programmed death 1 homolog (PD-1H, also called VISTA) is a promising target she has been focusing on. She is interested in both basic and translational immunological studies and has been actively collaborating with clinical fellows and pharmaceutical company to translate her studies into the clinic.


讲座摘要/Abstract:

Cancer immunotherapies targeting the B7-H1/PD-1 pathway, have achieved high objective response rates in patients, with durable responses in a broad spectrum of large and disseminated late-stage human malignancies. By searching the genomic database with the IgV region of PD-1, we identified a new immune modulating molecule named PD-1 homolog (PD-1H, also called VISTA). PD-1H is expressed mainly on immune cells. We found that PD-1H can work as an inhibitory ligand on antigen presenting cells to inhibit T cell responses. PD-1H expressed on either myeloid immune cells or myeloid derived tumor cells plays important roles in the induction of immune suppression. Blocking this pathway will boost immune responses against tumors. Meanwhile, we found PD-1H can also be a coinhibitory receptor on T cells. PD-1H deficiency results in spontaneous murine autoimmune dermatitis resembling human cutaneous lupus. Stimulation of PD-1H signaling using an agonist monoclonal antibody reduces cutaneous and autoimmune lupus in the canonical murine model of lupus. Further, we found both human discoid lupus erythematosus (DLE) lesions and lesions from mouse cutaneous lupus model express higher levels of PD-1H than normal skin. Being manipulated in opposite ways (by antagonist or agonist antibody), PD-1H could be potential immunotherapeutic target for both cancer and autoimmune treatment.


讲座联系人/Contact:

生命科学学院

于文越 yuwenyue@westlake.edu.cn